EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

PanGen Biotech Inc (222110) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of PanGen Biotech Inc KRW 2,825, price KRW 4,805, upside -41.2%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7222110009

PB Thin data Sep 24, 2026

PanGen Biotech Inc

222110 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 2,825 KRW · Strongly overvalued (−41%)
!Quality 33/100
!Expensive Growth (revenue 5y +16.7 %/yr)
✓Solidly profitable · 15.1% net margin (TTM)
!Low debt · negative free cash flow
✓Ranks above peers (7/8)
!Moderate moat 46/100
!Evidence only low, so the estimate is less certain
!Weak on past: 29 out of 100
Watch PanGen Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

11,600 KRW 3,840 KRW Fair Value 2,825 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 3,840 KRW – 11,600 KRW · fair‑value band 1,463 KRW – 4,232 KRW · the 4,805 KRW price screens above the 2,825 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow PanGen Biotech in your weekly email

Every Wednesday you see whether PanGen Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production.

Show more

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.

Stock analysis

PanGen Biotech Inc (222110) currently trades at 4,805 KRW, while our model-based Fair Value estimate is 2,825 KRW, implying the stock looks roughly 70.1% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 7,375 KRW per share, and 2 of the 15 models we run sit above the 4,805 KRW price.

Bear case: the Economic Profit group reads lowest at 1,336 KRW, and 13 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 1,463 KRW (bear) to 4,232 KRW (bull), the price of 4,805 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PanGen Biotech Inc reported revenue of 13.4B KRW in FY2025 versus 7.9B KRW in FY2021, a compound +14.0%/yr. Reported net income was 2.1B KRW in FY2025.

Key figures

Market cap 64.8B KRW (≈ $45.4M) · P/S ratio 4.49 · Net margin 15.3% · Return on equity 7.3% · Return on assets (EBIT) −8.4% · Operating margin 12.9% · Revenue (TTM) 13.7B KRW · Revenue growth (YoY) +8.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −41%, 222110 screens richer than that median.

Fair Value models

Bear 1,463 KRW Fair Value 2,825 KRW Bull 4,232 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV 1,192 KRW 1,336 KRW 1,460 KRW 74
ROIC Compounder 1,192 KRW 1,336 KRW 1,460 KRW 72
Owner Earnings 3,480 KRW 7,375 KRW 15,249 KRW 71
All 15 models by family
DCF Models
Owner Earnings 3,480 KRW 7,375 KRW 15,249 KRW 71
Earnings-Based
Graham-Dodd 1,033 KRW 7,206 KRW 10,113 KRW 63
Lynch FV 2,279 KRW 3,255 KRW 4,232 KRW 61
PEG = 1.0 2,279 KRW 3,255 KRW 4,232 KRW 57
EPV 1,192 KRW 1,336 KRW 1,460 KRW 74
Multiples
P/E Multiple 2,507 KRW 3,343 KRW 4,179 KRW 63
P/S Multiple 1,938 KRW 2,583 KRW 3,229 KRW 58
P/B Multiple 1,938 KRW 2,583 KRW 3,229 KRW 55
EV/EBIT 1,702 KRW 2,176 KRW 2,650 KRW 66
EV/EBITDA 2,591 KRW 3,361 KRW 4,132 KRW 67
EV/Revenue 1,294 KRW 1,729 KRW 2,165 KRW 54
Asset-Based
NCAV (Graham) 1,109 KRW 1,486 KRW 2,218 KRW 54
Economic Profit
Residual Income 1,762 KRW 1,837 KRW 1,916 KRW 71
ROIC Compounder 1,192 KRW 1,336 KRW 1,460 KRW 72
Growth Earnings
Growth-Adj P/E 3,114 KRW 4,449 KRW 5,784 KRW 67

Open the full fair value analysis →

Notify me when 222110 reaches fair value

Put 222110 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 33/100

Of which business quality 35 · Market factors (momentum, volatility) 35

Profitability 39
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 59
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 17
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Start year 2020 (pandemic). Over 10 years: +13.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−59.8% (2020) → 11.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

222110 screens 70% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare PanGen Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 6/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −41% · Above median
Profitability
Return on equity (TTM) 7% · Top 25%
Return on assets 3% · Top 25%
Net margin (TTM) 15% · Above median
Operating margin (TTM) 13% · Above median
Growth and dividend
Revenue growth 8% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)42 · sector 0
PAST (return on equity)29 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PanGen Biotech Inc · Fair Value
2,825 KRW −70%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PanGen Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/222110

Frequently asked questions

Is PanGen Biotech Inc (222110) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,825 KRW versus a price of 4,805 KRW, about −41% upside (overvalued).
What is the fair value of 222110?
Our model-based fair value for PanGen Biotech Inc is 2,825 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,805 KRW.
What is the quality score of 222110?
PanGen Biotech Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PanGen Biotech Inc (222110)?
Our model-based price target is the fair value of 2,825 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 1,463 KRW, optimistic scenario 4,232 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the PanGen Biotech Inc stock forecast for 2026?
Our models put fair value at 2,825 KRW, about −41% upside versus a price of 4,805 KRW (overvalued). Cautious scenario 1,463 KRW, optimistic scenario 4,232 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of PanGen Biotech Inc (222110)?
PanGen Biotech Inc reported trailing-twelve-month revenue of about 13.7B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of PanGen Biotech Inc (222110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PanGen Biotech Inc it is 2,825 KRW per share (as of Sep 24, 2026), against a price of 4,805 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is PanGen Biotech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 222110 trades above its calculated fair value: price 4,805 KRW, fair value 2,825 KRW, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 222110?
No. The price is what the market pays today (4,805 KRW); the fair value is what the company's own numbers justify (2,825 KRW). For PanGen Biotech Inc the two are 1,980 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is PanGen Biotech Inc worth?
The market values PanGen Biotech Inc at about 64.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,805 KRW; our models calculate a fair value of 2,825 KRW per share.
What do the bullish and bearish scenarios say about 222110?
Our models span a range for PanGen Biotech Inc: cautious scenario 1,463 KRW, base 2,825 KRW, optimistic 4,232 KRW per share (as of Sep 24, 2026, price 4,805 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PanGen Biotech Inc (222110)?
Balance-sheet figures for PanGen Biotech Inc (as of Sep 24, 2026): return on equity 7.3%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 222110 from its 52-week high?
PanGen Biotech Inc trades at 4,805 KRW, about 35% below its 52-week high of 7,340 KRW and 11% above the low of 4,330 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,825 KRW is for.
Which stocks are comparable to PanGen Biotech Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PanGen Biotech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 4,805 KRW, calculated fair value 2,825 KRW (−41%), Quality Score 33/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 222110 calculated?
We run PanGen Biotech Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,825 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. PanGen Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PanGen Biotech Inc (222110)?
The closing price on Sep 23, 2026 was 4,805 KRW. Our model-based fair value is 2,825 KRW, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PanGen Biotech Inc right now?
The price sits above even our optimistic bull case (4,232 KRW). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (1,463 KRW to 4,232 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PanGen Biotech Inc

How large is the market capitalisation of PanGen Biotech Inc (222110)?
The market capitalisation of PanGen Biotech Inc is 64.8B KRW (≈ $45.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PanGen Biotech Inc (222110)?
The price-to-sales ratio of PanGen Biotech Inc is 4.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PanGen Biotech Inc (222110)?
The net margin of PanGen Biotech Inc is 15.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PanGen Biotech Inc (222110)?
The return on equity (ROE) of PanGen Biotech Inc is 7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PanGen Biotech Inc (222110)?
On an EBIT basis the return on assets of PanGen Biotech Inc is −8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PanGen Biotech Inc (222110)?
The operating margin of PanGen Biotech Inc is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PanGen Biotech Inc (222110)?
Revenue at PanGen Biotech Inc is growing +8.4% versus a year earlier (3y avg +27.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PanGen Biotech Inc (222110)?
Earnings per share at PanGen Biotech Inc are growing −2.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PanGen Biotech Inc (222110) generate?
The free cash flow of PanGen Biotech Inc is −548M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PanGen Biotech Inc (222110) carry?
The net debt of PanGen Biotech Inc is 2.0B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PanGen Biotech Inc in the live analysis

One click puts PanGen Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.